Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156090 · ClinicalTrials.gov registry record
A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 141
- Enrollment target
NCT01156090 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 141 participants.
The verdict
NCT01156090 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hypersensitivity infusion reactions to Vectibix (Panitumumab)will be captured. In patients who experienced hypersensitivity reactions, the following information will also be collected: premedication, treatment cycle symptoms that were experienced during chemotherapy, changes required in subsequent Vectibix (Panitumumab) or chemotherapy treatment, and outcome of the hypersensitivity reaction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01156090
The ClinicalTrials.gov registry entry for NCT01156090 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01156090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01156090 about?
NCT01156090 is a clinical study titled "A Retrospective Cohort Study of Infusion Reactions Due to Vectibix". The purpose of this study is to identify approximately 100 - 150 patients who have received Vectibix (Panitumumab) in offices and clinics located in Tennessee, North Carolina, South Carolina, and North Georgia from February 2004 - April 2009. Information regarding the incidence and severity of hyper...
What is the current status of trial NCT01156090?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2010-06. Estimated completion is 2013-01.
Who is sponsoring clinical trial NCT01156090?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.